hyaluronic acid (YYD302) / Yooyoung Pharma - LARVOL DELTA

A Multicenter, Randomized, Double-Blinded, Parallel-Group, Placebo-Controlled Phase I/IIa Study to Evaluate the Efficacy and Safety of a Single Intra-Articular Injection of YYD302 in Patients with Knee Osteoarthritis. (PubMed, J Clin Med) - "While the rate and frequency of consuming the rescue drug continued to increase in the placebo group until 12 weeks, there was no change in the test groups. Our findings showed that YYD302, especially 2 mL of YYD302, reduced pain and improved knee joint function compared to the placebo."

Clinical • Journal • P1/2 data • Immunology • Osteoarthritis • Pain • Rheumatology

Intra-Articular Injection of a Novel DVS Cross-Linked Hyaluronic Acid Manufactured by Biological Fermentation (YYD302) in Patients With Knee Osteoarthritis: A Double-Blind, Randomized, Multicenter, Noninferiority Study. (PubMed, Clin Ther) - P3 | "The results of this study support that YYD302 is comparable to Synovian in terms of the efficacy and safety of the intra-articular injection treatment for osteoarthritis of the knee joint. Furthermore, YYD302 provided faster improvements in some efficacy assessments compared with Synovian. ClinicalTrials.gov identifier: NCT03561779."

Clinical • Head-to-Head • Journal • Dermatology • Immunology • Osteoarthritis • Pain • Rheumatology

Clinical Trial of YYD302 (Phase3) for Treatment of Osteoarthritis of the Knee (clinicaltrials.gov) - P3; N=184; Completed; Sponsor: Yooyoung Pharmaceutical Co., Ltd.; Recruiting ➔ Completed

Clinical • Trial completion • Immunology • Osteoarthritis • Pain • Rheumatology